Zyomyx Signs Deal with BD Biosciences to Access Antibodies for Protein Chip Content | GenomeWeb

Protein chip maker Zyomyx of Hayward, Calif., has entered into an agreement for access to BD Biosciences’ antibody collection, Zyomyx said.

Under the terms of the deal, Zyomyx will have access to BD Biosciences’ antibodies for use in protein biochip development. BD Biosciences will also develop other antibodies exclusively for Zyomyx. The companies did not disclose financial specifics of the agreement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.